Zentalis Pharmaceuticals, Inc. (ZNTL)
| Market Cap | 1.69B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -181.68M |
| Shares Out | 56.98M |
| EPS (ttm) | -3.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 592,501 |
| Open | 28.19 |
| Previous Close | 28.51 |
| Day's Range | 27.82 - 29.75 |
| 52-Week Range | 17.33 - 87.19 |
| Beta | 1.88 |
| Analysts | Buy |
| Price Target | 83.84 (+182.0%) |
| Earnings Date | Aug 10, 2022 |
About ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for ZNTL stock is "Buy." The 12-month stock price forecast is 83.84, which is an increase of 182.00% from the latest price.
News
Why Zentalis Pharmaceuticals (ZNTL) Might Surprise This Earnings Season
Zentalis Pharmaceuticals (ZNTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update
Strengthened leadership team with the appointment of additional industry veterans, including CEO Dr. Kimberly Blackwell and Chairman Dave Johnson
Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference
NEW YORK and SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary
NEW YORK and SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President
NEW YORK and SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule th...
Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock
NEW YORK and SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule th...
Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock
NEW YORK and SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule th...
Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update
Announced initial data on ZN-c3 in combination with chemotherapy in advanced ovarian cancer and interim data on ZN-c3 in uterine serous carcinoma (USC) at AACR
Pfizer Injects $25M Via Equity In Zentalis Pharma
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) will sell 953,834 common shares at $26.21 per share to Pfizer Inc (NYSE: PFE) for $25 million. The offering is expected to close by April 29.
Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer
Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells
Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 Weeks
The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals, Inc. (ZNTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wa...
Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR
ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts
Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Adva...
ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts
Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
NEW YORK and SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule ...
Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022
Updated data from Phase 1 expansion cohort of ZN-c3 in uterine serous carcinoma (USC) will be presented during a mini symposium session Updated data from Phase 1 expansion cohort of ZN-c3 in uterine ser...
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update
Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to Wee1 Inhibitor, ZN-c3, for the treatment of uterine serous carcinoma (USC)
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
NEW YORK and SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021
Webcast to be held on Thursday, December 16 at 11:00 a.m. EST Webcast to be held on Thursday, December 16 at 11:00 a.m. EST
Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uteri...
Potentially registrational Phase 2 trial of ZN-c3 in USC is underway, with initial enrollment and safety update expected in 2H 2022 Potentially registrational Phase 2 trial of ZN-c3 in USC is underway, ...
Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabin...
Initial results are expected in 2H 2022 Initial results are expected in 2H 2022
Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of it...
NEW YORK and SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule ...
Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles
Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patien...
NEW YORK and SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...
Zentera Therapeutics Announces Closing of $75 Million Series B Financing
Proceeds will be used to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China Proceeds will be used to...